In vitro and in vivo Anticholinesterase Activity of the Volatile Oil of the Aerial Parts of Ocimum basilicum L. and O. africanum Lour. Growing in Egypt

Loading...
Thumbnail Image

Date

2014

Journal Title

Journal ISSN

Volume Title

Type

Article

Publisher

World Academy of Science, Engineering and Technology, International Journal of Medical, Health, Biomedical, Bioengineering and Pharmaceutical Engineering

Series Info

World Academy of Science, Engineering and Technology, International Journal of Medical, Health, Biomedical, Bioengineering and Pharmaceutical Engineering;3

Abstract

In this study, the in vitro anticholinesterase activity of the volatile oils of both O. basilicum and O. africanum was investigated and both samples showed significant activity. The major constituents of the two oils were isolated using several column chromatographies. Linalool, 1,8-cineol and eugenol were isolated from the volatile oil of O. basilicum and camphor was isolated from the volatile oil of O. africanum. The anticholinesterase activities of the isolated compounds were also evaluated where 1,8-cineol showed the highest inhibitory activity followed by camphor. To confirm these activities, learning and memory enhancing effects were tested in mice. Memory impairment was induced by scopolamine, a cholinergic muscarinic receptor antagonist. Anti-amnesic effects of both volatile oils and their terpenoids were investigated by the passive avoidance task in mice. We also examined their effects on brain acetylcholinesterase activity. Results showed that scopolamineinduced cognitive dysfunction was significantly attenuated by administration of the volatile oils and their terpenoids, eugenol and camphor, in the passive avoidance task and inhibited brain acetylcholinesterase activity. These results suggest that O. basilicum and O. africanum volatile oils can be good candidates for further studies on Alzheimer’s disease via their acetylcholinesterase inhibitory actions.

Description

Keywords

University of Acetylcholinesterase, Ocimum basilicum

Citation

1] K. L. Alikatte, B. R. Aakondi, V. G. Yerragunta, P.R. Veerareddy, S. Palle, “Antiamnesic activity of Syzygium cumini against scopolamine induced spatial memory impairments in rats,” Brain Dev, vol. 34, pp. 844-851, 2012. [2] R.N. Kalaria, G.E. Maestre, R. Arizaga, R.P. Friedland, D. Galasko, K. Hall, J.A. Luchsinger, A. Ogunniyi, E.K. Perry, F. Potocnik, M. Prince, R. Stewart, A. Wimo, Z. Zhang, and P. Antuono, “Alzheimer’s disease and vascular dementia in developing countries: prevalence, management, and risk factors,” The Lancet Neurology, vol. 7, pp. 812– 826, 2008. [3] J.L. Cummings, H.V. Vinters, G.M. Cole, and Z.S. Khachaturian, “Alzheimer’s disease: etiologies, pathophysiology, cognitive reserve and treatment opportunities,” Neurology, vol. 51, S2–S17, 1988. [4] P.T. Francis, A.M. Palmer, M. Snape, and G.K. Wilcock, “The cholinergic hypothesis of Alzheimer’s disease: a review of progress,” Journal of Neurology Neurosurgery and Psychiatry, vol. 66, pp. 137– 147, 1999. [5] D.K. Lahiri, M.R. Farlow, N.H. Greig, and K. Sambamurti, “Current drug targets for Alzheimer’s disease treatment,” Drug Development Research, vol. 56, pp. 267-281, 2002. [6] S. Thompson, K.L. Lanctot, and N. Herrmann, “The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer’s disease,” Expert Opinion on Drug Safety, vol. 3, pp. 425–440, 2004. 7] L. Fang, B. Kraus, J. Lehmann, J. Heilmann, Y. Zhang, and M. Decker, “Design and synthesis of tacrine–ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates,” Bioorganic and Medicinal Chemistry Letters, vol. 18, pp. 2905–2909, 2008. [8] V. Singh, S. Amdekar, and O. Verma, “Ocimum sanctum (tulsi): Biopharmacological activities”, Webmed central pharmacology, vol. 1, WMC001046, 2010. [9] A. Paton, “A synopsis of Ocimum L. (Labiatae) in Africa,” Kew Bull, vol. 47, pp. 405, 1992. [10] N-A. Zeggwagh, and M. Eddouks, “Anti-hyperglycaemic and hypolipidemic effects of Ocimum basilicum aqueous extract in diabetic rats,” American Journal of Pharmacology and Toxicology, vol. 2, issue 3, pp. 123-129, 2007. [11] M.S. Akhtar, and M. Munir, “Evaluation of the gastric antiulcerugenic effects of Solanum nigrum, Brassica oleracea and Ocimum basilicum in rats,” J Ethnopharmacol, vol. 27, pp. 163–171, 1989. [12] K. Ilhan, Y. Nazife, and B. Mehlika, “Antimicrobial activity of various extracts of Ocimum basilicum L. and observation of the inhibition effect on bacterial cells by use of scanning electron microscopy,” Afr J Trad CAM , vol. 5, pp. 363–369, 2008. [13] T. Dasgupta, A. R. Rao, and P. K. Yadava, “Chemomodulatory efficacy of Basil leaf (Ocimum basilicum) on drug metabolizing and antioxidant enzymes, and on carcinogen-induced skin and forestomach papillomagenesis,” Phytomedicine, vol. 11, pp. 139–151, 2004. [14] O. Stajkovic, B. Tanja, M. Dragana, S. Slavisa, V. G. Branka, S. Draga, and K. V. Jelena, “Antimutagenic properties of Basil (Ocimum basilicum L.) in Salmonella typhimurium TA100,” Food Technol Biotechnol, vol. 45, pp. 213–217, 2007. [15] E. Capecka, A. Mareczek, and B. M. Leja, “Antioxidant activity of fresh and dry herbs of some Lamiaceae species,” Food Chem, vol. 93, pp. 223–226, 2005. [16] A. Umar, G. Imam, W. Yimin, and P. Kerim, “Anti-hypertensive effects of L. on blood pressure in renovascular hypertensive rats,” Hyperten Res, vol. 33, pp. 723–730, 2010. [17] A. F. Blank, Y.R. Rosa, J. L. Carvalho Filho, C.A. Santos, M. F. Arrigoni-Blank, E. S. Niculau, et al, “A diallel study of yield components and essential oil constituents in basil (Ocimum basilicum L.), ” Ind Crops Prod, vol. 38, pp. 93-98, 2012. [18] R. J. Grayer, G. C. Kite, F. J. Goldstone, S. E. Bryan, A. Paton, and E. Putievsky, “Infraspecific taxonomy and essential oil chemotypes in sweet basil, Ocimum basilicum, ” Phytochemistry, vol. 43, pp.1033- 1039, 1996. [19] E. Klimánková, K. Holadova, J. Hajslova, T. Cajka, J. Poustka, and M. Koudela, “Aroma profiles of five basil (Ocimum basilicum L.) cultivars grown under conventional and organic conditions,” Food Chem, vol. 107, pp. 464-472, 2008. [20] S. Amrani, H. Harnafi, D. Gadi, H. Mekhfi, A. Legssyer, M. Aziz, et al, “Vasorelaxant and anti-platelet aggregation effects of aqueous Ocimum basilicum extract, ” J Ethnopharmacol, vol. 125, pp. 157-162, 2009. [21] H. Harnafi, M. Aziz, and S. Amrani, “Sweet basil (Ocimum basilicum L.) improves lipid metabolism in hypercholesterolemic rats, ” E Spen M.E. Jarvik, and R. Kopp, “An improved one-trial learning situation in mice,” Psychol. Rep, vol. 21, pp. 221–224, 1967. [22] D.K. Rush, “Scopolamine amnesia of passive avoidance: a deficit of information acquisition,” Behav. Neural Biol, vol. 50, pp. 255–274, 1988. [23] G. L. Ellman, K. D. Courtney, V. Andres, and R. M. Featherstone, “A new and rapid colorimetric determination of actetylcholinesterase activity”, Biochem. Pharmacol, vol. 7, pp. 88-95, 1961. [24] M.E. Jarvik, and R. Kopp, “An improved one-trial learning situation in mice,” Psychol. Rep, vol. 21, pp. 221–224, 1967. [25] D. Dhingra, M. Parle, and S.K. Kulkarni, “Memory enhancing activity of Glycyrrhiza glabra in mice,” J. Ethnopharmacol, vol. 91, pp. 361– 365, 2004. [26] M. Dokania, K. Kishore, and P. Sharma, “Effect of Ocimum sanctum extract on sodium nitrite-induced experimental amnesia in mice,” Thai J Pharm Sci, vol. 35, pp. 123-130, 2011. [27] S. Kumar, S. Rao, S. Nayak, and N. Sareesh, “Effect of Ocimum sanctum (Linn) extract on restraint stress induced behavioral deficits in male wistar rats, ” Pharmacol Online, vol. 3, pp. 394-404, 2007. [28] H. Joshi and M. Parle, “Cholinergic basis of memory improving effect of Ocimum tenuiflorum linn”, Indian J Pharm Sci, vol. 68, pp. 364, 2006. [29] K. S. Bora, S. Arora, and R. Shri, “Role of Ocimum basilicum L. in prevention of ischemia and reperfusion-induced cerebral damage, and motor dysfunctions in mice brain”, J Ethnopharmacol, vol. 137, pp. 1360-1365, 2011. [30] I. Gülçin, M. Elmasta, and H. Y. Aboul-Enein, “Determination of antioxidant and radical scavenging activity of Basil (Ocimum basilicum L. Family Lamiaceae) assayed by different methodologies,” Phytother Res, vol. 21, pp. 354-361, 2007. [31] H. J. Chang, H. J. Kim, and H. S. Chun, “Quantitative structure-activity relationship (QSAR) for neuroprotective activity of terpenoids,” Life Sciences, vol. 80, no. 9, pp. 835–841, 2007. [32] L. Mu, J. Kou, D. Zhu, and B. Yu, “Comparison of neuroprotective effects of flavonoids, terpenoids, and their combinations from Ginkgo biloba on ischemia-reperfusion—injured mice”, Pharmaceutical Biology, vol. 45, no. 9, pp. 728–733, 2007. [33] I. Kivrak, M. E. Duru, M. Ozturk, N. Mercan, M. Harmandar, and G. Topcu, “Antioxidant, anticholinesterase and antimicrobial constituents from the essential oil and ethanol extract of Salvia potentillifolia”, Food Chemistry, vol. 116, no. 2, pp. 470- 479, 2009. [34] K. Shiomi, “Meroterpenoids with various biological activities produced by fungi,” Pure and Applied Chemistry, vol. 71, no. 6, pp. 1059–1064, 1999. [35] S. U. Savelev, E. J. Okello, and E. K. Perry, “Butyryl- and acetylcholinesterase inhibitory activities in essential oils of Salvia species and their constituents”, Phytotherapy Research, vol. 18, no. 4, pp. 315–324, 2004.